Literature DB >> 30918075

Interferon Gamma Inhibits Varicella-Zoster Virus Replication in a Cell Line-Dependent Manner.

Akhalesh K Shakya1,2, Seong K Kim3,2, Dennis J O'Callaghan1,2.   

Abstract

The major immediate early 62 (IE62) protein of varicella-zoster virus (VZV) is delivered to newly infected cell nuclei, where it initiates VZV replication by transactivating viral immediate early (IE), early (E), and late (L) genes. Interferon gamma (IFN-γ) is a potent cytokine produced following primary VZV infection. Furthermore, VZV reactivation correlates with a decline in IFN-γ-producing immune cells. Our results showed that treatment with 20 ng/ml of IFN-γ completely reduced intracellular VZV yield in A549 lung epithelial cells, MRC-5 lung fibroblasts, and ARPE-19 retinal epithelial cells at 4 days post-VZV infection. However, IFN-γ reduced virus yield only 2-fold in MeWo melanoma cells compared to that of untreated cells. IFN-β significantly inhibited VZV replication in both ARPE-19 and MeWo cells. In luciferase assays with VZV open reading frame 61 (ORF61) promoter reporter plasmid, IFN-γ abrogated the transactivation activity of IE62 by 95%, 97%, and 89% in A549, ARPE-19, and MRC-5 cells, respectively. However, IFN-γ abrogated IE62's transactivation activity by 16% in MeWo cells, indicating that IFN-γ inhibits VZV replication as well as IE62-mediated transactivation in a cell line-dependent manner. The expression of VZV IE62 and ORF63 suppressed by IFN-γ was restored by JAK1 inhibitor treatment, indicating that the inhibition of VZV replication is mediated by JAK/STAT1 signaling. In the presence of IFN-γ, knockdown of interferon response factor 1 (IRF1) increased VZV replication. Ectopic expression of IRF1 reduced VZV yields 4,000-fold in MRC-5 and ARPE-19 cells but 3-fold in MeWo cells. These results suggest that IFN-γ blocks VZV replication by inhibiting IE62 function in a cell line-dependent manner.IMPORTANCE Our results showed that IFN-γ significantly inhibited VZV replication in a cell line-dependent manner. IFN-γ inhibited VZV gene expression after the immediate early stage of infection and abrogated IE62-mediated transactivation. These results suggest that IFN-γ blocks VZV replication by inhibiting IE62 function in a cell line-dependent manner. Understanding the mechanisms by which IFN-γ plays a role in VZV gene programming may be important in determining the tissue restriction of VZV.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  IE62; interferon gamma; interferon response factor 1; nitric oxide; replication inhibition; transactivation; varicella-zoster virus

Mesh:

Substances:

Year:  2019        PMID: 30918075      PMCID: PMC6613748          DOI: 10.1128/JVI.00257-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

Review 1.  Genomic structure and organization of varicella-zoster virus.

Authors:  J I Cohen
Journal:  Contrib Microbiol       Date:  1999

Review 2.  The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion.

Authors:  D E Levy; A García-Sastre
Journal:  Cytokine Growth Factor Rev       Date:  2001 Jun-Sep       Impact factor: 7.638

3.  Cellular factors and IE62 activation of VZV promoters.

Authors:  William T Ruyechan; Hua Peng; Min Yang; John Hay
Journal:  J Med Virol       Date:  2003       Impact factor: 2.327

4.  Physical interaction between two varicella zoster virus gene regulatory proteins, IE4 and IE62.

Authors:  M L Spengler; W T Ruyechan; J Hay
Journal:  Virology       Date:  2000-07-05       Impact factor: 3.616

5.  Physical and functional interaction between the Y-box binding protein YB-1 and human polyomavirus JC virus large T antigen.

Authors:  M Safak; G L Gallia; S A Ansari; K Khalili
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  IL-12, IFN-gamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella.

Authors:  S Torigo; T Ihara; H Kamiya
Journal:  Microbiol Immunol       Date:  2000       Impact factor: 1.955

7.  Physical and functional interaction between the varicella zoster virus IE63 and IE62 proteins.

Authors:  Jennifer M Lynch; Terri K Kenyon; Charles Grose; John Hay; William T Ruyechan
Journal:  Virology       Date:  2002-10-10       Impact factor: 3.616

8.  Role for gamma interferon in control of herpes simplex virus type 1 reactivation.

Authors:  E Cantin; B Tanamachi; H Openshaw
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 9.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

10.  Interaction between the varicella zoster virus IE62 major transactivator and cellular transcription factor Sp1.

Authors:  Hua Peng; Hongying He; John Hay; William T Ruyechan
Journal:  J Biol Chem       Date:  2003-07-10       Impact factor: 5.157

View more
  4 in total

Review 1.  Manipulation of the Innate Immune Response by Varicella Zoster Virus.

Authors:  Chelsea Gerada; Tessa M Campbell; Jarrod J Kennedy; Brian P McSharry; Megan Steain; Barry Slobedman; Allison Abendroth
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

2.  Interferon Gamma Inhibits Equine Herpesvirus 1 Replication in a Cell Line-Dependent Manner.

Authors:  Seong K Kim; Akhalesh K Shakya; Dennis J O'Callaghan
Journal:  Pathogens       Date:  2021-04-16

3.  Varicella-Zoster virus ORF9 is an antagonist of the DNA sensor cGAS.

Authors:  Jonny Hertzog; Wen Zhou; Gerissa Fowler; Rachel E Rigby; Anne Bridgeman; Henry Tw Blest; Chiara Cursi; Lise Chauveau; Tamara Davenne; Benjamin E Warner; Paul R Kinchington; Philip J Kranzusch; Jan Rehwinkel
Journal:  EMBO J       Date:  2022-06-07       Impact factor: 14.012

4.  Transcriptome Analysis Reveals the Role of Cellular Calcium Disorder in Varicella Zoster Virus-Induced Post-Herpetic Neuralgia.

Authors:  Songbin Wu; Shaomin Yang; Mingxi Ou; Jiamin Chen; Jiabing Huang; Donglin Xiong; Wuping Sun; Lizu Xiao
Journal:  Front Mol Neurosci       Date:  2021-05-17       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.